SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SangStat Med. (SANG) - 10 of 10 analysts say Strong Buy
SANG 4.760-0.8%Jan 12 3:57 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: James Silverman who wrote (46)10/27/1997 3:21:00 AM
From: Philip Aaron Etttedgui  Read Replies (1) of 184
 
Spring-summer 1998 is when generic cyclosporin will get approved. SANG is about 2 years ahead of any other generic cyclosporin competitor. Competitors have to run clinical trials and need marketing and sales force. Expect SANG to capture 75% of the $1.2 billion dollar cyclosporin market until then. FY 1999 EPS forecast is $5.00/share plus.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News